Table 1 Characteristics of patients between PET positive and negative groups
From: Metabolic tumor burden on postsurgical PET/CT predicts survival of patients with gastric cancer
Characteristics | All patients (n = 376) | PET findings | P values | |
|---|---|---|---|---|
Positive (n = 236) | Negative (n = 140) | |||
Age (mean ± SD) | 51.1 ± 18.4 | 51.4 ± 18.1 | 50.7 ± 18.9 | 0.734* |
Gender | 0.827† | |||
Men (%) | 180 (47.9%) | 114 (48.3%) | 66 (47.1%) | |
Women (%) | 196 (52.1%) | 122 (51.7%) | 74 (52.9%) | |
Pathological type of primary tumor | < 0.001† | |||
PAC/TAC | 112 (29.8%) | 83 (35.2%) | 29 (20.7%) | |
PDAC | 180 (47.9%) | 117 (49.6%) | 63 (45.0%) | |
SRC/MAC | 84 (22.3%) | 36 (15.3%) | 48 (34.3%) | |
Lauren classifications | 0.020† | |||
Intestinal | 130 (34.6%) | 92 (39.0%) | 38 (27.1%) | |
Non-intestinal | 246 (65.4%) | 144 (61.0%) | 102 (72.9%) | |
T stage of primary tumor | < 0.001† | |||
T1 | 95 (25.3%) | 37 (15.7%) | 58 (41.4%) | |
T2 | 112 (29.8%) | 75 (31.8%) | 37 (26.4%) | |
T3 | 133 (35.4%) | 101 (42.8%) | 32 (22.9%) | |
T4 | 36 (9.6%) | 23 (9.7%) | 13 (9.3%) | |
Gastrectomy | 0.484† | |||
Total | 178 (47.3%) | 115 (48.7%) | 63 (45.0%) | |
Subtotal | 198 (52.7%) | 121 (51.3%) | 77 (55.0%) | |
Lymphovascular invasion | < 0.001† | |||
Yes | 195 (51.9%) | 146 (61.9%) | 49 (35.0%) | |
No | 181 (48.1%) | 90 (38.1%) | 91 (65.0%) | |
Clinical restage | < 0.001† | |||
Locoregional recurrence | 140 (37.2%) | 140 (59.3%) | … | |
Distant metastasis | 96 (25.6%) | 96 (40.7%) | … | |
None | 140 (37.2%) | … | 140 (100%) | |
Postsurgical adjuvant treatment | < 0.001† | |||
Yes | 220 (58.5%) | 175 (74.2%) | 45 (32.1%) | |
No | 156 (41.5%) | 61 (25.8%) | 95 (67.9%) | |
Intervals between surgery and PET/CT (month) | 8.6 ± 4.2 | 8.3 ± 4.2 | 9.1 ± 4.1 | 0.103* |
Postsurgical MTBWB on PET/CT | … | |||
SUVWBmax | … | 8.9 ± 4.7 | … | |
MTVWB (cm3) | … | 289.7 ± 256.3 | … | |
TLGWB (cm3) | … | 1002.1 ± 733.6 | … | |
Median OS (month) | 19 (5–60) | 16 (5–59) | 29 (12–60) | < 0.001‡ |